Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Gross Margin (2016)

Viridian Therapeutics, Inc.\DE (VRDN) has 3 years of Gross Margin data on record, last reported at 136.74% in Q4 2016.

  • For Q4 2016, Gross Margin fell 473469.0% year-over-year to 136.74%; the TTM value through Dec 2016 reached 52.0%, up 4487.0%, while the annual FY2016 figure was 49.99%, 4738.0% up from the prior year.
  • Gross Margin reached 136.74% in Q4 2016 per VRDN's latest filing, up from 36.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 4871.43% in Q4 2015 and bottomed at 15.17% in Q3 2015.
  • Average Gross Margin over 3 years is 461.81%, with a median of 55.72% recorded in 2016.
  • Peak YoY movement for Gross Margin: skyrocketed 488017bps in 2015, then crashed -473469bps in 2016.
  • A 3-year view of Gross Margin shows it stood at 8.75% in 2014, then skyrocketed by 55804bps to 4871.43% in 2015, then tumbled by -97bps to 136.74% in 2016.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 136.74% in Q4 2016, 36.0% in Q3 2016, and 33.0% in Q2 2016.